X-ELIO secures 245 GWh renewable PPA with pharmaceutical companies

Through Energize Program from Schneider Electric, X-ELIO will provide 245 GWh of renewable energy annually to four pharmaceutical companies for 10 years starting 2026.

author-image
By Karthik Srivasthav G
New Update
The Lorca Solar project, expected to begin operations in early 2026, will supply renewable energy to pharmaceutical companies through a virtual PPA agreement.

The Lorca Solar project, expected to begin operations in early 2026, will supply clean energy to pharmaceutical companies through a VPPA agreement. Image Source: X-ELIO

X-ELIO, headquartered in Spain, has signed a multi-buyer Power Purchase Agreement with four pharmaceutical companies under the Energize program. Thermo Fisher Scientific, Haleon, Gilead Sciences, and GSK will purchase 245 GWh of renewable energy annually for a decade. The energy will be sourced from X-ELIO’s 369 MW Lorca Solar project which is expected to begin operations by early 2026. X-ELIO has integrated social and local responsibility into the Lorca Solar project through a Community Plan. The VPPA, part of the Energize program, a supply chain renewables initiative designed and delivered by Schneider Electric, is endorsed by PSCI and X-ELIO. The PSCI initiative aligns with efforts to support the pharmaceutical sector’s supply chain decarbonization. 

Advertisment {'id': '67a31fe485152d67baef73d2', 'source_name': 'X-ELIO', 'source_link': 'https://www.x-elio.com/the-pharmaceutical-program-energize-partners-with-x-elio-to-advance-its-climate-goals/', 'contact_name': 'Isabel Ruiz ', 'contact_email': '[email protected]'}
Advertisment

Scan to join our channel

QR Code
Latest Stories